Immunocore (NASDAQ:IMCR – Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Immunocore to announce earnings of ($0.1749) per share and revenue of $152.10 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 2:00 AM ET.
Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. On average, analysts expect Immunocore to post $0.03 EPS for the current fiscal year and $0.22 EPS for the next fiscal year.
Immunocore Stock Up 1.7%
Shares of NASDAQ IMCR opened at $30.29 on Tuesday. The company’s 50-day simple moving average is $32.22 and its 200-day simple moving average is $31.80. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -82.77 and a beta of 0.81. Immunocore has a 52-week low of $27.50 and a 52-week high of $40.71.
Wall Street Analysts Forecast Growth
IMCR has been the subject of several recent research reports. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Monday, October 26th. Mizuho lifted their target price on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Morgan Stanley set a $43.00 price target on Immunocore in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immunocore presently has an average rating of “Moderate Buy” and a consensus price target of $55.86.
Get Our Latest Analysis on Immunocore
About Immunocore
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
Read More
- Five stocks we like better than Immunocore
- Check Point’s Turnaround Could Be Closer Than Investors Think
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
